Tuesday, 5 June 2018

AbbVie's rheumatoid arthritis drug succeeds in late-stage study

(Reuters) - Abbvie Inc said on Tuesday its experimental drug upadacitinib met the main goals of a late-stage study in patients with moderate-to-severe rheumatoid arthritis.


No comments:

Post a Comment